Merck is playing defense against Summit Therapeutics with a $3.3 billion licensing deal announced Thursday for a cancer drug.

As Merck prepares for its blockbuster immunotherapy Keytruda to face generic competition, it’s investing in a new cancer drug from LaNova.

Q3 2024 Earnings Conference Call November 14, 2024 8:00 AM ETCompany ParticipantsConstantin Fest - Head of Investor ...

Serum-free Media market Growth is Driven by Technological Advancements & Growing Demand for Cell-Based Therapies AUSTIN, TX, UNITED STATES, November 14, 2024 /EINPresswire / -- According to SNS ...

The company is paying China-based biotech LaNova Medicines $588 million for the same type of bispecific antibody drug that ...

Merck (MRK) and LaNova Medicines, a privately held clinical-stage biotechnology company, announced that Merck has entered into an exclusive ...

Germany’s Merck KGaA (MRK: DE) was trading 5% lower as Thursday’s trading day neared its end, after the company announced its ...

The global protein expression market is expected to reach USD 4.82 billion in 2029 from USD 3.41 billion in 2024 at a CAGR of ...

In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...

As the rollout of its recently launched pulmonary arterial hypertension (PAH) drug Winrevair ramps up, Merck is continuing ...